9HFY | pdb_00009hfy

Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor.

Bardiot, D., McGowan, D.C., Gupta, K., Deval, J., Chang, S., Jekle, A., Liu, C., Stevens, S., Serebryany, V., Tauchert, M.J., Maskos, K., Stoycheva, A.D., Ren, S., Jaisinghani, R., Faucher, M.O., Lin, T.I., Boland, S., Chaltin, P., Marchand, A., Wuyts, J., De Jonghe, S., Jochmans, D., Anugu, S., Baloju, V., Deta, K., Welch, M., Leyssen, P., Neyts, J., Laporte, M., Abdelnabi, R., Hu, H., Zhang, P., Le, K., Chanda, S., Smith, D.B., Raboisson, P., Beigelman, L., Symons, J.A., Blatt, L., Vandyck, K.

(2025) J Med Chem 

• PubMed: 40586480 Search on PubMed
• DOI: https://doi.org/10.1021/acs.jmedchem.5c00088
• Primary Citation of Related Structures:  
  9HFX, 9HFY


• PubMed Abstract: 
  

  The SARS-CoV-2 outbreak of 2019 had a devastating impact on global health and economies worldwide. The viral cysteine protease (3CLpro) is responsible for viral polypeptide bond cleavages and is therefore an essential target to inhibit viral replication. Here, we report the discovery of an orally available, reversible covalent inhibitor of the SARS-CoV-2 main protease that is also highly active across other human coronaviruses and demonstrated oral efficacy in a Syrian hamster infection model at low plasma concentrations. Projection of pharmacokinetics (PK) in humans, based on PK studies in preclinical species and enhanced in vitro/in vivo efficacy of ALG-097558 ( 7 ) indicated the potential for BID dosing without the need for ritonavir, the PK boosting component of Paxlovid. After preclinical safety and pharmacological studies, ALG-097558 has progressed to phase 1 clinical trials.

   View More

---

Organizational Affiliation: 

CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium.